Advertisement

Long-Term Treatment with Ruxolitinib for Patients With Myelofibrosis: 5-Year Update From the Randomized, Double-Blind, Placebo-Controlled, Phase 3 COMFORT-I Trial

The final COMFORT-I results continue to support ruxolitinib as an effective treatment for patients with intermediate-2/high-risk myelofibrosis.

 J Hematol Oncol

click me